{"classes":[{"categories":[{"measurements":[{"comment":"The sample size is too small to calculate standard error.","groupId":"OG000","spread":"NA","value":"22"},{"comment":"The sample size is too small to calculate standard error.","groupId":"OG001","spread":"NA","value":"18"},{"groupId":"OG002","spread":"8.2","value":"37.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Mucositis will be scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Duration of Oral Mucositis WHO Grade 3 or higher measured as the days of severe oral mucositis.","dispersionType":"Standard Error","groups":[{"description":"Subjects were administered a 7 mg loading dose subcutaneously followed by a 3.5 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG000","title":"Phase 1: Group 1"},{"description":"Subjects were administered a 14 mg loading dose subcutaneously followed by a 7 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG001","title":"Phase 1: Group II"},{"description":"Subjects were administered a 28 mg loading dose subcutaneously followed by a 14 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG002","title":"Phase 2: Group III"}],"paramType":"MEAN","populationDescription":"only the patients that had mucositis were evaluated for duration","reportingStatus":"POSTED","timeFrame":"6 month 6 months","title":"Duration of Radiation-induced Mucositis","type":"SECONDARY","unitOfMeasure":"days"}